ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1326 • ACR Convergence 2020

    Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study

    Sali Merjanah1, Mohamad Bittar2 and Marina Magrey3, 1Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 2The University of Tennessee Health Science Center, Memphis, TN, 3Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…
  • Abstract Number: 1332 • ACR Convergence 2020

    Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?

    Milad Baniaamam1, Sjoerd C. Heslinga2, M. Louis Handoko3, Thelma C. Konings3, Otto Kamp3, Vokko P. van Halm4, J. Christiaan van Denderen1, Irene van der Horst-Bruinsma2 and Mike Nurmohamed5, 1Reade, Amsterdam, Netherlands, 2Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 3Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 4Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, 5Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR).  AVR in AS is caused by…
  • Abstract Number: 1331 • ACR Convergence 2020

    Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study

    Dionicio Ángel Galarza-Delgado1, José Ramón Azpiri López2, Iris Jazmín Colunga Pedraza3, Diana Elsa Flores Alvarado4, Octavio Ilizaliturri Guerra4, Paola Fernanda Frausto Lerma3, Itzel Corina Zárate Salinas2, Alejandra Pérez Villar3, Mayra Alejandra Reyes Soto3, Salvador Lugo Pérez2 and Andrea Cecilia Garza Acosta5, 1Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Cardiology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, 3Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, 4Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, 5Radiology Service, Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease (CVD). The carotid ultrasound, which measures both carotid intima-media thickness (cIMT) and…
  • Abstract Number: 1337 • ACR Convergence 2020

    Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis

    Olga Compán1, Maria Elisa Acosta2, Sonia Pastor2, Guadalupe Manzano Canabal2, Luis Gomez-Lechon Quiros3, Cristina Hidalgo Calleja4, Noelia Cubino2, Ricardo Usategui5, Rogelio Gonzalez Sarmiento5, Olga Martinez Gonzalez6, Ana Isabel Turrión2, Javier Del Pino-Montes2 and Carlos Montilla Morales2, 1Hospital Universitario de Salamanca, ´Salamanca, Spain, 2Hospital Universitario de Salamanca, Salamanca, Spain, 3Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, 4Hospital Universitario Salamanca, Salamanca, Spain, 5Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, 6Hospital Universitario de Salamanca, Zamora, Spain

    Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…
  • Abstract Number: 1339 • ACR Convergence 2020

    COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes

    Rebecca Haberman1, Rochelle Castillo1, Alan Chen2, Di Yan1, Deborah Ramirez2, Vaish Sekar2, Robert Lesser2, Gary Solomon2, Andrea Neimann2, Rebecca Blank1, Peter Izmirly3, Dan Webster4, Alexis Ogdie5, Andrea Troxel2, Samrachana Adhikari2 and Jose Scher1, 1NYU School of Medicine, New York City, 2NYU Langone Health, New York City, 3New York University, New York, NY, 4Sage Bionetworks, Seattle, 5Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation. Affecting initially China, New York City (NYC) quickly…
  • Abstract Number: 1334 • ACR Convergence 2020

    Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study

    Andrea Delle Sedie1, Emanuele Calabresi1, Ilaria Romagnoli1, Linda Carli2 and Marta Mosca2, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence…
  • Abstract Number: 1329 • ACR Convergence 2020

    Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?

    Mai Farouk1, Salwa Moussa1 and Rowaida Abdou1, 1Rhuematology Ain Shams University Hospitals, Cairo, Egypt

    Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis that can cause remarkable joint damage (1). Subclinical cardiovascular disease (CVD) due to…
  • Abstract Number: 1342 • ACR Convergence 2020

    Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK

    Filip Van den Bosch1, Peter Nash2, James Cheng-Chung Wei3, Francisco Blanco4, Vassilis Tsekouras5, Chuanbo Zang6, Daniela Graham7, Edmund Arthur8, Pamela Selema6, Bonnie Vlahos6 and Atul Deodhar9, 1Ghent University Hospital, Ghent, Belgium, 2School of Medicine Griffith University, Brisbane, Queensland, Australia, 3Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), 4INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, 5Pfizer, Nicosia, Cyprus, 6Pfizer, Collegeville, PA, 7Pfizer, Groton, PA, 8Pfizer, Peapack, NJ, 9Oregon Health & Science University, Portland, OR

    Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…
  • Abstract Number: 1345 • ACR Convergence 2020

    Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials

    Peter Nash1, Pascal Richette2, Laure Gossec3, Antonio Marchesoni4, Koji Kato5, Erin Blondell6, Elizabeth Lesser6, Reva M McCaskill6, Dai Feng6, Jaclyn K Anderson6 and Eric Ruderman7, 1School of Medicine Griffith University, Brisbane, Queensland, Australia, 2Department of Rheumatology, Lariboisière Hospital, Paris, France, 3Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 4ASST Gaetano Pini-CTO, Milano, Italy, 5AbbVie Inc, North Chicago, IL, 6AbbVie Inc., North Chicago, IL, 7Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Approximately 40% of PsA patients (pts) on advanced therapy are on monotherapy.1,2 Upadacitinib (UPA) has shown efficacy and safety in pts with active PsA…
  • Abstract Number: 1346 • ACR Convergence 2020

    Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis

    Runsheng Wang1, Abhijit Dasgupta2 and Michael Ward3, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2NIAMS, Bethesda, 3National Institutes of Health, Bethesda, MD

    Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous.  In clinical practice, both patients and…
  • Abstract Number: 1341 • ACR Convergence 2020

    Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study

    Vibeke Strand1, Philip Mease2, Enrique Soriano3, Mitsumasa Kishimoto4, Carlo Salvarani5, Nemanja Damjanov6, Jaclyn K Anderson7, Erin Blondell7, Patrick Zueger7, Christopher Saffore7 and Dafna Gladman8, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, 4Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, 5Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, 6University of Belgrade Medical School, Belgrade, Serbia, 7AbbVie Inc., North Chicago, IL, 8Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
  • Abstract Number: 1352 • ACR Convergence 2020

    Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension

    Joseph Merola1, Frank Behrens2, Alan Kivitz3, Philip Mease4, Iain McInnes5, Barbara Ink6, Deepak Assudani7, Paulatsya Joshi7, Jason Coarse8 and Christopher Ritchlin9, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 3Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, 4Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 5Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 6UCB Pharma, Slough, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Raleigh, NC, 9Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…
  • Abstract Number: 1349 • ACR Convergence 2020

    Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis

    Laura Coates1, Christopher Ritchlin2, Laure Gossec3, Philip Helliwell4, Proton Rahman5, Elizabeth Hsia6, Alexa Kollmeier7, Xie Xu8, Chetan Karyekar9, May Shawi10, Wim Noël11, Yusang Jiang12, Shihong Sheng12, Prasheen Agarwal12 and Philip Mease13, 1University of Oxford, Oxford, United Kingdom, 2Department of Medicine, University of Rochester Medical Center, Rochester, NY, 3Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 6Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 7Janssen Research & Development, LLC, La Jolla, CA, 8Janssen Research & Development, LLC, San Marcos, CA, 9Janssen Global Services, LLC, Horsham, PA, 10Janssen Global Services, LLC, Toronto, ON, Canada, 11Janssen Medical Affairs, LLC, Beerse, Belgium, 12Janssen Research & Development, LLC, Spring House, PA, 13Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody that specifically binds to the p19-subunit of IL-23. GUS has demonstrated efficacy across the various manifestations of…
  • Abstract Number: 1344 • ACR Convergence 2020

    Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced

    Christopher Ritchlin1, Philip Helliwell2, Wolf-Henning Boehncke3, Elizabeth Hsia4, Alexa Kollmeier5, Ramanand Subramanian6, Xie Xu7, Shihong Sheng6, Yusang Jiang6, Bei Zhou6 and Atul Deodhar8, 1Department of Medicine, University of Rochester Medical Center, Rochester, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Geneva University Hospitals, Geneva, Switzerland, 4Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 5Janssen Research & Development, LLC, La Jolla, CA, 6Janssen Research & Development, LLC, Spring House, PA, 7Janssen Research & Development, LLC, San Marcos, CA, 8Oregon Health & Science University, Portland, OR

    Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis (PsO). At Week 24 of the…
  • Abstract Number: 1236 • ACR Convergence 2020

    Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials

    Sebastian Unizony1, Joseph Dang2, Jian Han3, Margaret Michalska2 and Jennie H. Best2, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, 3Genentech, South San Francisco, CA

    Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
  • « Previous Page
  • 1
  • …
  • 714
  • 715
  • 716
  • 717
  • 718
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology